Home/Pipeline/AIM-MASH

AIM-MASH

Metabolic dysfunction-Associated Steatohepatitis

FDA Qualified for TrialsActive

Key Facts

Indication
Metabolic dysfunction-Associated Steatohepatitis
Phase
FDA Qualified for Trials
Status
Active
Company

About PathAI

PathAI is a leading AI-powered pathology company that has developed a comprehensive platform, AISight®, for digital pathology image management and AI algorithm deployment. It serves two primary markets: biopharma clients, for whom it provides translational research, clinical trial services, and diagnostic development, and anatomic pathology laboratories, which use its platform for workflow digitization and AI-assisted diagnostics. The company has achieved significant regulatory milestones, including FDA clearance for its AISight® Dx platform for primary diagnosis and FDA qualification for its AIM-MASH tool for clinical trials, and collaborates with major industry players like Labcorp and top biopharma firms.

View full company profile

Other Metabolic dysfunction-Associated Steatohepatitis Drugs

DrugCompanyPhase
SomaSignal Test for MASH/NASHSomaLogicDevelopment
MASH/Liver Health ScreeningIMA Clinical ResearchNot Applicable (Service)